RO7020531

Also Known As:

((1S)-1-((2S,4R,5R)-5-(5-amino-2-oxo-(1,3)thiazolo(4,5-d)pyrimidin-3-yl)-4-hydroxyoxolan-2-yl)propyl)acetate; ruzotolimod

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

1.	Chronic Hepatitis B 01/01/2023 - "TLR7 agonist RO7020531 versus placebo in healthy volunteers and patients with chronic hepatitis B virus infection: a randomised, observer-blind, placebo-controlled, phase 1 trial." 01/01/2020 - "RO7020531, an oral prodrug of a TLR7 agonist, is in clinical development as part of a curative regimen against chronic hepatitis B. "
2.	Human Influenza (Influenza) 01/01/2023 - "In the patient cohorts, there was one severe adverse event (influenza-like illness with 170 mg of RO7020531) and one serious adverse event (moderate influenza-like illness with a 3-day hospitalisation in a treatment-naive patient receiving RO7020531). "
3.	Infections 01/01/2023 - "Due to acceptable safety and tolerability, RO7020531 should continue to be developed for the treatment of patients with chronic HBV infection. " 01/01/2023 - "We aimed to assess the safety and tolerability of RO7020531 (also called RG7854), a prodrug of the TLR7 agonist RO7011785, in healthy volunteers and patients with chronic HBV infection. " 01/01/2023 - "In part 2, nucleoside or nucleotide analogue-suppressed patients with chronic HBV infection were randomly assigned (4:1) within cohorts 1-3 (150 mg, 150 mg, or 170 mg) to receive either RO7020531 or placebo and treatment-naive patients with chronic HBV infection were randomly assigned (3:1) in cohort 4 to receive either 150 mg of RO7020531 or placebo. "